中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 36 Issue 6
Jun.  2020
Turn off MathJax
Article Contents

New thoughts about renaming nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2020.06.001
  • Published Date: 2020-06-20
  • Nonalcoholic fatty liver disease( NAFLD) is a multisystem disease involving metabolic disorder and is more common in patients with obesity and type 2 diabetes mellitus( T2 DM),with similar adverse outcomes to these two comorbidities. For a long time,NAFLD has emphasized liver lesions and outcomes of liver diseases,and when treating T2 DM according to the current clinical guidelines for diabetes,endocrinologists often neglect the screening,diagnosis,and treatment of liver lesions. Therefore,in clinical practice,NAFLD renamed as metabolic-associated fatty liver disease has important practical significance. Strategies for T2 DM prevention and treatment aiming at reducing liver lipid content require multidisciplinary cooperation,and prevention and treatment of obesity,fatty liver disease,and diabetes with the same concepts can help to implement the prevention and treatment of the most common chronic diseases.

     

  • loading
  • [1] ESLAM M,NEWSOME PN,SARIN SK,et al. A new definition for metabolic dysfunction-associated fatty liver disease:An international expert consensus statement[J]. J Hepatol,2020.[Online ahead of print]
    [2] LI J,ZOU B,YEO YH,et al. Prevalence,incidence,and outcome of non-alcoholic fatty liver disease in Asia,1999-2019:A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2019,4(5):389-398.
    [3] FRIEDMAN SL,NEUSCHWANDER-TETRI BA,RINELLA M,et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med,2018,24(7):908-922.
    [4] MOHAMMED E,ARUN JS,JACOB G,et al. MAFLD:A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology,2020,158(7):1999-2014.
    [5] GASTALDELLI A,CUSI K. From NASH to diabetes and from diabetes to NASH:Mechanisms and treatment options[J].JHEP Rep,2019,1(4):312-328.
    [6] AMARAPURKAR DN,HASHIMOTO E,LESMANA LA,et al.How common is non-alcoholic fatty liver disease in the AsiaPacific region and are there local differences?[J]. J Gastroenterol Hepatol,2007,22(6):788-793.
    [7] POLYZOS SA,KOUNTOURAS J,MANTZOROS CS. Obesity and nonalcoholic fatty liver disease:From pathophysiology to therapeutics[J]. Metabolism,2019,92:82-97.
    [8] BRIL F,CUSI K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes:A call to action[J]. Diabetes Care,2017,40(3):419-430.
    [9] BRIL F,CUSI K. Nonalcoholic fatty liver disease:The new complication of type 2 diabetes mel itus[J]. Endocrinol Metab Clin North Am,2016,45(4):765-781.
    [10] MARCHESINI G,DAY CP,DUFOUR JF,et al. EASL-EASDEASO clinical practice guidelines for the management of non-alcoholic fatty liver disease[J]. J Hepatol,2016,64(6):1388-1402.
    [11] Chinese Society of Endocrinology,Chinese Medical Association. Consensus for diagnosis and treatment of nonalcoholic fatty liver diseases and metabolic disorders(2nd Edition)[J].J Clin Hepatol,2018,34(10):2103-2108.(in Chinese)中华医学会内分泌学分会.非酒精性脂肪性肝病与相关代谢紊乱诊疗共识(第二版)[J].临床肝胆病杂志,2018,34(10):2103-2108.
    [12] BIAN H,ZHU X,XIA M,et al. Impact of type 2 diabetes on nonalcoholic steatohe patitis and advanced fibrosis in patients with nonalcoholic fatty liver disease[J]. Endocr Pract,2020,26(4):444-453.
    [13] PORIES WJ,MACDONALD KG Jr,MORGAN EJ,et al. Surgical treatment of obesity and its effect on diabetes:10-y follow-up[J]. Am J Clin Nutr,1992,55(2 Suppl):582s-585s.
    [14] LEAN ME,LESLIE WS,BARNES AC,et al. Primary care-led weight management for remission of type 2 diabetes(DiRECT):An open-label,cluster-randomised trial[J]. Lancet,2018,391(10120):541-551.
    [15] LEAN M,LESLIE WS,BARNES AC,et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes:2-year results of the DiRECT openlabel,cluster-randomised trial[J]. Lancet Diabetes Endocrinol,2019,7(5):344-355.
    [16] TAYLOR R,AL-MRABEH A,SATTAR N. Understanding the mechanisms of reversal of type 2 diabetes[J]. Lancet Diabetes Endocrinol,2019,7(9):726-736.
    [17] TAYLOR R,BARNES AC. Can type 2 diabetes be reversed and how can this best be achieved? James Lind Alliance research priority number one[J]. Diabet Med,2019,36(3):308-315.
    [18] PETRICK JL,KELLY SP,ALTEKRUSE SF,et al. Future of hepatocellular carcinoma incidence in the united states forecast through 2030[J]. J Clin Oncol,2016,34(15):1787-1794.
    [19] HESTER D,GOLABI P,PAIK J,et al. Among medicare patients with hepatocellular carcinoma,non-alcoholic fatty liver disease is the most common etiology and cause of mortality[J]. J Clin Gastroenterol,2020,54(5):459-467.
    [20] ANSTEE QM,REEVES HL,KOTSILITI E,et al. From NASH to HCC:Current concepts and future challenges[J]. Nat Rev Gastroenterol Hepatol,2019,16(7):411-428.
    [21] FRIEDMAN SL,NEUSCHWANDER-TETRI BA,RINELLA M,et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med,2018,24(7):908-922.
    [22] ALUKAL JJ,THULUVATH PJ. Reversal of NASH fibrosis with pharmacotherapy[J]. Hepatol Int,2019,13(5):534-545.
    [23] FIORUCCI S,BIAGIOLI M,DISTRUTTI E. Future trends in the treatment of non-alcoholic steatohepatitis[J]. Pharmacol Res,2018,134:289-298.
    [24] JOHNSTON MP,PATEL J,BYRNE CD. Multi-drug approaches to NASH:What's in the development pipeline?[J]. Expert Opin Investig Drugs,2020,29(2):143-150.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1255) PDF downloads(443) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return